摘要
目的探讨肾康注射液联合缬沙坦治疗慢性肾小球肾炎的临床效果。方法将2016年11月—2018年7月收治的96例慢性肾小球肾炎患者以随机数字表法分为对照组48例,观察组48例,对照组给予缬沙坦治疗,观察组在对照组基础上加用肾康注射液。观察两组治疗效果,治疗前、治疗8周后肾功能、尿蛋白、细胞免疫功能变化及不良反应发生情况。结果治疗总有效率观察组为95.83%(46/48),与对照组81.25%(39/48)对比,明显较高(P<0.05);治疗前,两组肾功能、尿蛋白水平差异无统计学意义(P>0.05),治疗8周后,观察组血尿素氮(BUN)、血肌酐(SCr)及24 h尿定量(24 hUPQ)与同期对照组对比,明显较低(P<0.05);治疗前,两组细胞免疫功能无统计学意义(P>0.05),治疗8周后,观察组血清CD4^+、CD4^+/CD8^+与同期对照组对比,明显较高,CD8^+与同期对照组对比,明显较低(P<0.05);不良反应发生率观察组为14.58%(7/48),与对照组12.50%(6/48)对比,无统计学意义(P>0.05)。结论肾康注射液联合缬沙坦治疗慢性肾小球肾炎,效果确切,可显著改善肾功能,降低尿蛋白水平,增强细胞免疫功能,且安全性良好,值得推广。
Objective To investigate the clinical effect of Shenkang Injection combined with valsartan in the treatment of chronic glomerulonephritis.Methods Ninety-six patients with chronic glomerulonephritis admitted from Nov 2016 to Jul 2018 were randomly divided into the control group(48 cases)and the observation group(48 cases).The control group was treated with valsartan,and the observation group was given Shenkang Injection on the basis of the control group.We observed the therapeutic effects,the renal function,urine protein,cellular immune function before and after 8 weeks of treatment and recorded the adverse reactions of two groups.Results The total effective rate was 95.83%(46/48)in the observation group,which was significantly higher compared with that of the control group(81.25%,39/48)(P<0.05).Before treatment,there was no significant difference in renal function and urine protein levels between the two groups(P>0.05).After 8 weeks of treatment,the blood urea nitrogen(BUN),serum creatinine(SCr)and 24-hour urinary protein quantity(24 hUPQ)in the observation group were significantly lower compared with those of the control group(P<0.05).Before treatment,there was no significant difference in cellular immune function between the two groups(P>0.05).After 8 weeks of treatment,serum levels of CD4^+and CD4^+/CD8^+in the observation group were significantly higher compared with those of the control group.The CD8^+was significantly lower compared with that of the control group(P<0.05).The incidence of adverse reactions was 14.58%(7/48)in the observation group,and there was no significant difference compared with that of the control group(12.50%,6/48)(P>0.05).Conclusion Shenkang Injection combined with valsartan in the treatment of chronic glomerulonephritis has clear effect and can significantly improve the renal function of patients,reduce urine protein levels,enhance cellular immune function,and has good safety,worth promoting.
作者
王永丽
杨秀勇
WANG Yongli;YANG Xiuyong(Department of Nephrology,Zunyi First People's Hospital,Zunyi 563000,Guizhou,China;Department of Endocrinology,Zunvi First People's Hospital,Zunyi 563000,Guizhou,China)
出处
《中华中医药学刊》
CAS
北大核心
2020年第9期72-74,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教发[2016]328)。
关键词
慢性肾小球肾炎
肾康注射液
缬沙坦
肾功能
细胞免疫功能
尿蛋白
chronic glomerulonephritis
Shenkang Injection
valsartan
renal function
cellular immune function
urine protein
